Enhanced Tumor Uptake of Boronophenylalanine by Means of Osmotic Blood-Brain Barrier Disruption in Glioma—Bearing Rats

  • Weilian Yang
  • Rolf F. Barth
  • David E. Carpenter
  • Joseph H. Goodman


The endothelial cells of capillaries within the brain constitute a barrier for the delivery of water-soluble drugs to this anatomic site. Intracarotid infusions of hyperosmotic solutions of mannitol disrupt these tight endothelial cell junctions both in normal brain and intracerebral tumors1. Neuwelt et al. have shown that osmotic blood-brain barrier (BBB) disruption can increase the uptake of both low and high molecular weight substances by brain tumors in experimental animals and humans2,3. The purpose of the present study was to determine if BBB disruption could significantly and specifically enhance the uptake of p-boronophenylalanine (BPA), which has been used as a capture agent for boron neutron capture therapy (BNCT) of intracerebral gliomas and melanomas in experimental animal studies4,5. The following report describes our studies on the effects of BBB disruption on the uptake of BPA using the F98 rat glioma, which simulates human glioblastoma multiforme in its biologic behavior.


Evans Blue Boron Concentration Boron Neutron Capture Therapy High Molecular Weight Substance Capture Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    C.D. Fenstermacher and A.L. Cowles, Theoretic limitation of intracarotid infusion in brain tumor chemotherapy. Cancer Treat. Rep. 61: 519–526, 1977PubMedGoogle Scholar
  2. 2.
    E.A. Neuwelt, J. Howieson, and E.P. Frenkel, Therapeutic efficacy ofmultiagent chemotherapy with drug enhancement by blood-brain barrier modification in glioblastoma, Neurosurgery. 19: 573–582, 1986.PubMedCrossRefGoogle Scholar
  3. 3.
    E.A. Neuwelt, H.D Specht, P.A. Barnett, S.A Dahlborg, R.N. Abbey Miley, S.M. Larson, P. Brown, K.F. Eckerman, K.E Hellström, I. Hellström. Increased delivery of tumor-specific monoclonal antibodies to brain after blood-brain barrier modification in patients with melanoma metastatic to central nervous. Neurosurgery. 20: 885–895, 1987.PubMedCrossRefGoogle Scholar
  4. 4.
    K.Z Matalka, R.F. Barth, A.E. Staubus, M.L Moeschberger, J.A. Coderre. Neutron capture therapy of rat glioma using boronophenylalanine as a capture agent. Radiat. Res. 137, 44–51. 1993.CrossRefGoogle Scholar
  5. 5.
    K.Z Matalka, M.Q. Bailey, R.F. Barth, A.E. Staubus, A.H. Soloway, M.L Moeschberger, J.A. Coderre, and E.K. Rofstad. Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. Cancer Res. 53: 3308–3313, 1993.PubMedGoogle Scholar
  6. 6.
    N.R Clendenon, R.F. Barth, WA. Gordon, J.H. Goodman, F. Alam, A.E. Staubus, C.P. Boesel, A.J.Yates, M.L. Moeschberger, R.G. Fairchild and J.A. Kalef-Ezra. Boron neutron capture therapy of a rat glioma. Neurosurgery. 26: 47–55, 1990.PubMedCrossRefGoogle Scholar
  7. 7.
    E.A Neuwelt, N.P. Barnett, I. Hellström, K.E. Hellström, P. Beaumier, C.I. Mccormick, R.M Weigel, Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragment to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res. 48: 4725–4729, 1988.PubMedGoogle Scholar
  8. 8.
    R.F. Barth, D.M. Adams, A.H Soloway, E.B Mechetner, F. Alam, and A.K.M. Anisuzzaman. Determination of boron in tissues and cells using direct-current plasma atomic emmission spectroscopy. Anal. Chem. 63: 890–893, 1991.PubMedCrossRefGoogle Scholar
  9. 9.
    A.K Kumagai, J.B Eisenberg and W.M Pardridge, Absorptive-mediated endocystosis cationized albumin and a B-endorphin-cationized almumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J. Biol. Chem. 262: 15214–15219, 1987.PubMedGoogle Scholar
  10. 10.
    W.R Shapiro, R.M Voorhies, E.M Hiesiger, P.B Sher, G.A Basler and L.E. Lipschutz, Pharmacokinetics of tumor cell exposure to [’4C] methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barrier in rat brain tumor: a quantitative autoradiographic study. Cancer Res. 48: 694–701, 1988.PubMedGoogle Scholar
  11. 11.
    T. Lahann, C. Sills, G. Hematillake, T. Dymock and G. Daniell. Cardiovascular toxicities associated with i.v. administration of p-BPA formulation. in Advances in Neutron Capture Therapy, eds. Soloway, A.H., Barth, R.F. and Carpenter, D.E., Plenum Press. New York, 1993,pp 513–517.Google Scholar
  12. 12.
    E.A. Neuwelt, P.A. Barnett, K.E. Hellström, I. Hellström, C.I. Mccormick, and F.L. Ramsey. Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J Nucl Med. 35: 1831–1841, 1994.PubMedGoogle Scholar
  13. 13.
    W. Yang, R.F. Barth, D.E. Carpenter, M.L. Mocschberger, and J.H. Goodman. Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption. Neurosurgery 38: 985–992, 1996.PubMedCrossRefGoogle Scholar
  14. 14.
    W. Yang, R.F. Barth, J.H. Rotary, M.L. Moeschberger, D.E. Carpenter, D.D. Joel, M.M. Nawrocky, and J.H. Goodman. Enhanced survival of glioma bearing rats following boron neutron capture therapy with blood brain barrier disruption and intracarotid injection of boronophenylalanine. J. Neuro-oncol., 1997 (in press).Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Weilian Yang
    • 1
  • Rolf F. Barth
    • 1
  • David E. Carpenter
    • 2
  • Joseph H. Goodman
    • 2
  1. 1.Department of Pathology College of MedicineThe Ohio State UniversityColumbusUSA
  2. 2.Division of Neurosurgery College of MedicineThe Ohio State UniversityColumbusUSA

Personalised recommendations